Eczema drug sits at the center of this dementia and brain health question.
If you or someone you care for uses Dupixent for eczema, there is a emerging safety concern your prescribing physician may not have mentioned — and it involves cancer. A 2024 study published in the Journal of the American Academy of Dermatology found that patients taking Dupixent (dupilumab) had a 4.59 times higher relative risk of developing cutaneous T-cell lymphoma, a rare but serious skin cancer, compared to non-users. Despite this finding and over 300 adverse event reports filed with the FDA, Dupixent’s label still carries no warning about this risk as of February 2026. For older adults, particularly those managing both skin conditions and cognitive decline, the stakes of a missed or delayed cancer diagnosis are especially high.
Dupixent, manufactured by Sanofi and Regeneron Pharmaceuticals, has been used by more than 800,000 patients and is projected to generate $20 billion in sales in 2026 alone. It is a blockbuster drug by every measure. But a growing body of research, a string of lawsuits, and an active FDA investigation suggest the full picture of its safety profile has not reached most patients or their doctors. This article examines what the research actually shows, why misdiagnosis is a particular danger for older adults, what the FDA is doing, and what practical steps patients and caregivers should consider.
Table of Contents
- What Is Your Doctor Not Telling You About Dupixent and Cancer Risk?
- How Dupixent May Mask a Rare Skin Cancer
- The FDA’s Slow Response and What It Means for Patients
- What Caregivers and Patients Should Do Right Now
- The Lawsuits and What They Signal About Future Developments
- Why This Matters Especially in Dementia Care
- Looking Ahead — What to Watch For in 2026
- Conclusion
- Frequently Asked Questions
What Is Your Doctor Not Telling You About Dupixent and Cancer Risk?
The core issue is straightforward: multiple independent analyses have linked Dupixent use to cutaneous T-cell lymphoma, and yet neither the drug’s label nor standard prescribing guidance reflects this. An FDA adverse-event analysis found that CTCL reports were approximately 30 times higher for Dupixent users compared to all other medications in its database. A separate study calculated the odds ratio at 4.10 for CTCL in Dupixent-treated atopic dermatitis patients. These are not small signals buried in statistical noise. And yet, when patients sit down with their dermatologist and weigh the pros and cons of starting a biologic, CTCL is almost certainly not part of the conversation — because the label does not require it to be.
This gap matters most for the population this site serves. Among the 39 documented CTCL cases worldwide following Dupixent use for eczema, 54.5 percent of affected patients were over age 60. Older adults already face higher baseline cancer risks, and those with dementia or cognitive impairment may not notice or be able to communicate new or changing skin symptoms. A caregiver who assumes a persistent rash is just the eczema acting up may unknowingly be watching an early-stage lymphoma go untreated. Meanwhile, 62 percent of CTCL cases following Dupixent use were diagnosed within the first year, meaning the window for vigilance is immediate.
How Dupixent May Mask a Rare Skin Cancer
Dupixent works by blocking IL-4 and IL-13 signaling, which are key drivers of the inflammation behind eczema. The problem is that by suppressing this specific inflammatory pathway, the drug may also mask the early signals of cutaneous T-cell lymphoma — specifically a subtype called mycosis fungoides. Mycosis fungoides closely mimics eczema in both clinical appearance and under the microscope, and it is extraordinarily rare, occurring in only about 6 cases per million people. dermatologists do not routinely biopsy for it because, in most cases, it would be an unreasonable thing to suspect.
There is a competing theory worth understanding. Some researchers argue that what looks like Dupixent “causing” CTCL may actually be an unmasking effect: certain patients may have been misdiagnosed with eczema when they actually had pre-existing CTCL all along, and the cancer only became apparent after Dupixent predictably failed to resolve it. This is a plausible explanation in some cases. However, even if unmasking accounts for a portion of the cases, it does not eliminate the clinical concern. If a drug delays the correct diagnosis of a cancer — whether by suppressing its visible symptoms or by reinforcing a dermatologist’s confidence in a wrong diagnosis — the outcome for the patient is the same. This distinction between causation and masking matters for scientists, but for a 70-year-old patient whose lymphoma has progressed to an advanced stage, the academic debate offers little comfort.
The FDA’s Slow Response and What It Means for Patients
In March 2025, the FDA added Dupixent and CTCL to its Potential Signals of Serious Risks list, based on its review of Q4 2024 adverse event reporting data and more than 300 reports of cutaneous T-cell lymphoma in Dupixent users. By September 2025, the agency confirmed it was formally evaluating whether new cancer warnings should be added to the drug’s label. As of February 2026, no label change has been made. To put this timeline in perspective, consider that the FDA flagged a potential cancer signal nearly a year ago and the drug’s prescribing information still says nothing about lymphoma.
During that year, physicians have continued prescribing Dupixent without any regulatory obligation to discuss CTCL risk with their patients. For caregivers of older adults with dementia, this is a practical problem. You cannot rely on the patient to advocate for themselves or to report suspicious skin changes to their doctor. And you cannot rely on the prescribing label to prompt the doctor to look for trouble. The responsibility, for now, falls on the caregiver to be informed and to ask direct questions.
What Caregivers and Patients Should Do Right Now
If someone in your care is currently taking Dupixent, do not stop the medication without consulting their doctor — abruptly discontinuing a biologic can trigger severe eczema flares. Instead, schedule a conversation with their dermatologist and ask specifically whether a biopsy has been performed to rule out CTCL, especially if the eczema has been resistant to treatment or has changed in character. Ask whether the rash has features that could be consistent with mycosis fungoides. A doctor who is aware of the emerging research will take this question seriously.
It is also worth understanding the alternatives and their tradeoffs. JAK inhibitors like RINVOQ (upadacitinib), CIBINQO (abrocitinib), and the topical Opzelura (ruxolitinib cream) are approved for eczema but carry their own FDA black box warnings for serious infections, major cardiovascular events, blood clots, cancer, and death. These sound alarming, but a 2025 systematic review of 43 studies found that real-world incidence rates of these serious events were low among dermatology patients specifically. In other words, every option on the table has risk — the question is which risks have been transparently communicated and which have not. Dupixent’s risk profile is the one currently under active federal investigation, and its label is the one that remains silent.
The Lawsuits and What They Signal About Future Developments
In October 2025, the first wrongful death lawsuit was filed in Tennessee. A woman alleged that her mother developed peripheral T-cell lymphoma shortly after starting Dupixent and died months later. Additional lawsuits followed, including one filed in Georgia in January 2026 by a woman who developed CTCL after using the drug. By February 2026, a motion was filed to consolidate 15 Dupixent lawsuits into a federal multidistrict litigation in the Northern District of Georgia. No MDL has been formally established, and there are no verdicts or settlements to date.
These lawsuits are still in their earliest stages, and their outcomes are uncertain. It is important not to read legal filings as scientific proof — plaintiffs’ attorneys select cases that support their theory, and defendants will present competing evidence. A large-scale 2025 study published in Frontiers in Medicine, which matched 7,840 Dupixent users against 7,840 controls, found that Dupixent did not increase overall lymphoma risk and may actually have partially reduced it compared to other systemic treatments. That study will almost certainly be central to Sanofi and Regeneron’s defense. The legal picture is genuinely unsettled, and anyone telling you the science is definitive in either direction is overstating the evidence.
Why This Matters Especially in Dementia Care
Dementia caregivers already manage a staggering number of medications, appointments, and behavioral challenges. Skin conditions like eczema are often treated as low-priority — something to manage, not something to worry about. But when a drug that treats a “manageable” skin condition may be hiding a rare cancer, the calculus changes.
A person with moderate-to-advanced dementia cannot tell you that a patch of skin feels different, that it has thickened, or that it itches in a new way. They cannot advocate for a second opinion or push back when a dermatologist dismisses a rash as routine. That job belongs to the caregiver, and it requires knowing that this concern exists in the first place.
Looking Ahead — What to Watch For in 2026
The next major milestone will be the FDA’s decision on whether to mandate a label change for Dupixent. If the agency requires a CTCL warning, it will fundamentally alter how the drug is prescribed and discussed with patients.
The MDL consolidation ruling will also shape the legal landscape — if a Dupixent MDL is established, it will signal that the courts see enough common ground in these cases to proceed efficiently, which typically accelerates discovery and may pressure settlement discussions. For now, the most important thing a caregiver or patient can do is stay informed and have a direct, documented conversation with their prescribing physician about whether CTCL has been considered and ruled out.
Conclusion
Dupixent has helped hundreds of thousands of people manage debilitating eczema, and for many, it remains an effective treatment. But the emerging research linking it to cutaneous T-cell lymphoma — a rare skin cancer that mimics eczema and disproportionately affects older adults — is a legitimate safety concern that has not yet made it onto the drug’s label. The FDA is investigating. Lawsuits are mounting.
And yet, most patients and their caregivers have heard nothing about it from their doctors, because the system has not yet required that conversation to happen. If you are caring for an older adult who takes Dupixent, bring this information to their next dermatology appointment. Ask for a skin biopsy if there is any doubt about the diagnosis. Document the conversation. You do not need to panic, but you do need to be the one asking the questions that the drug label has not yet prompted your doctor to answer.
Frequently Asked Questions
Has the FDA confirmed that Dupixent causes cancer?
No. As of February 2026, the FDA has placed Dupixent and CTCL on its Potential Signals of Serious Risks list and is formally evaluating whether to add cancer warnings to the label. It has not made a final determination.
How common is cutaneous T-cell lymphoma in Dupixent users?
There are 39 documented cases worldwide following Dupixent use for eczema out of more than 800,000 total patients. The absolute risk appears low, but the relative risk compared to non-users was found to be 4.59 times higher in one 2024 study.
Should I stop taking Dupixent?
Do not stop any biologic medication without consulting your doctor. Abruptly discontinuing Dupixent can cause severe eczema rebound. Instead, discuss the emerging CTCL research with your dermatologist and ask whether additional monitoring or testing is appropriate.
Are the alternative eczema drugs safer?
JAK inhibitors like RINVOQ and CIBINQO carry FDA black box warnings for serious infections, cardiovascular events, blood clots, cancer, and death — though real-world incidence rates have been low in dermatology patients. Every treatment option has risks; the key is ensuring those risks are transparently communicated.
Who is most at risk for CTCL after Dupixent use?
Among documented cases, 54.5 percent of patients who developed CTCL after Dupixent use were over age 60, and 62 percent were diagnosed within the first year of treatment.
Is there any evidence that Dupixent is safe regarding cancer risk?
Yes. A large 2025 study in Frontiers in Medicine with 7,840 patients per group found that Dupixent did not increase lymphoma risk and may have partially reduced it compared to other systemic treatments. The scientific picture remains genuinely mixed.
You Might Also Like
- Why Dermatologists Say You Should Never Use This Cream on Your Face
- This Prescription Ointment Works for Psoriasis But Has a Hidden Catch
- Can cold water swimming improve brain function as you age
For more, see Alzheimer’s Association — caregiving.
